Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1ΞΊ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 180
- Registration Number
- NCT02879318
- Locations
- π¨π¦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
π¨π¦Kingston Health Sciences Centre, Kingston, Ontario, Canada
π¨π¦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-08-17
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 180
- Registration Number
- NCT02870920
- Locations
- π¨π¦
CHUQ-Pavillon Hotel-Dieu de Quebec, Quebec City, Quebec, Canada
π¨π¦BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
π¨π¦Hopital de la Cite-de-la-Sante, Laval, Quebec, Canada
A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 108
- Registration Number
- NCT02866747
- Locations
- π«π·
Hopital Avicenne, Bobigny, France
π«π·Institut de Cancerologie de L'Ouest, Angers, France
π«π·Centre Georges Francois Leclerc, Dijon, France
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT02826434
- Locations
- πΊπΈ
New York University School of Medicine, New York, New York, United States
πΊπΈMassachusetts general Hospital, Boston, Massachusetts, United States
πΊπΈBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
- First Posted Date
- 2016-07-04
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 54
- Registration Number
- NCT02821754
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
- Conditions
- Interventions
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT02815995
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery
- Conditions
- HydronephrosisInfiltrating Bladder Urothelial Carcinoma Sarcomatoid VariantInfiltrating Bladder Urothelial Carcinoma, Micropapillary VariantInfiltrating Bladder Urothelial Carcinoma, Plasmacytoid VariantInfiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid VariantRenal Pelvis Urothelial CarcinomaStage II Bladder Urothelial Carcinoma AJCC v6 and v7Stage II Renal Pelvis Cancer AJCC v7Stage II Ureter Cancer AJCC v7Stage II Urethral Cancer AJCC v7
- Interventions
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT02812420
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
Study of Azacitidine and Durvalumab in Advanced Solid Tumors
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 28
- Registration Number
- NCT02811497
- Locations
- π¨π¦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Celgene
- Target Recruit Count
- 37
- Registration Number
- NCT02807454
- Locations
- πΊπΈ
UCLA Division of Hematology Oncology, Los Angeles, California, United States
π¨π¦Local Institution - 103, Saint John, New Brunswick, Canada
π¨π¦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2020-06-19
- Target Recruit Count
- 25
- Registration Number
- NCT02802098
- Locations
- πͺπΈ
H. Arnau de Vilanova Lleida, Lleida, Spain
πͺπΈHospital Universitario 12 de Octubre, Madrid, Spain
πͺπΈHospital RamΓ³n y Cajal, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.